JP2019508403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019508403A5 JP2019508403A5 JP2018540794A JP2018540794A JP2019508403A5 JP 2019508403 A5 JP2019508403 A5 JP 2019508403A5 JP 2018540794 A JP2018540794 A JP 2018540794A JP 2018540794 A JP2018540794 A JP 2018540794A JP 2019508403 A5 JP2019508403 A5 JP 2019508403A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleic acid
- polynucleotide sequence
- vaccine
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 claims 23
- 108091033319 polynucleotide Proteins 0.000 claims 20
- 102000040430 polynucleotide Human genes 0.000 claims 20
- 239000002157 polynucleotide Substances 0.000 claims 20
- 150000007523 nucleic acids Chemical class 0.000 claims 18
- 102000039446 nucleic acids Human genes 0.000 claims 17
- 108020004707 nucleic acids Proteins 0.000 claims 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 10
- 241000124008 Mammalia Species 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 108010017842 Telomerase Proteins 0.000 claims 6
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 239000002671 adjuvant Substances 0.000 claims 4
- 241000282472 Canis lupus familiaris Species 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 239000013612 plasmid Substances 0.000 claims 3
- 102000001327 Chemokine CCL5 Human genes 0.000 claims 2
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 2
- 102100037850 Interferon gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004520 electroporation Methods 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038707 Respiratory papilloma Diseases 0.000 claims 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000028996 humoral immune response Effects 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000021633 leukocyte mediated immunity Effects 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000001307 recurrent respiratory papillomatosis Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291601P | 2016-02-05 | 2016-02-05 | |
| US62/291,601 | 2016-02-05 | ||
| PCT/US2017/016557 WO2017136758A1 (en) | 2016-02-05 | 2017-02-03 | Cancer vaccines and methods of treatment using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019508403A JP2019508403A (ja) | 2019-03-28 |
| JP2019508403A5 true JP2019508403A5 (enExample) | 2020-03-19 |
| JP7123800B2 JP7123800B2 (ja) | 2022-08-23 |
Family
ID=59500919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018540794A Active JP7123800B2 (ja) | 2016-02-05 | 2017-02-03 | がんのワクチン及びそれを用いた処置の方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US11007255B2 (enExample) |
| EP (1) | EP3411122A4 (enExample) |
| JP (1) | JP7123800B2 (enExample) |
| KR (2) | KR20250002803A (enExample) |
| CN (2) | CN108883312B (enExample) |
| AU (1) | AU2017214656B2 (enExample) |
| BR (1) | BR112018015893A2 (enExample) |
| CA (1) | CA3013718C (enExample) |
| MX (2) | MX2018009506A (enExample) |
| WO (1) | WO2017136758A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250002803A (ko) * | 2016-02-05 | 2025-01-07 | 이노비오 파마수티컬즈, 인크. | 암 백신 및 이를 이용하는 치료 방법 |
| US20200147195A1 (en) * | 2017-05-26 | 2020-05-14 | The Wistar Institute Of Anatomy And Biology | Dtert vaccines and methods of treatment using the same |
| BR112020008512A2 (pt) | 2017-10-31 | 2020-10-06 | Pantarhei Bioscience B.V. | métodos imunoterapêuticos para tratamento e/ou prevenção do câncer pulmonar |
| CN111479585A (zh) * | 2017-12-13 | 2020-07-31 | 艾诺奥医药品有限公司 | 靶向boris的癌症疫苗和其用途 |
| EP3899024A4 (en) | 2018-12-21 | 2023-05-31 | Ionis Pharmaceuticals, Inc. | Modulators of hsd17b13 expression |
| WO2021259963A1 (en) | 2020-06-23 | 2021-12-30 | Pandora Endocrine Innovation B.V. | Immunization against wnt4 for treatment and prophylaxis of breast cancer |
| US20250026818A1 (en) | 2021-10-19 | 2025-01-23 | Sciencemed Spóka z ograniczon odpowiedzialnoci | Male contraception |
| WO2023237726A1 (en) | 2022-06-10 | 2023-12-14 | Pantarhei Oncology B.V. | An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer |
| WO2025146078A1 (en) * | 2024-01-04 | 2025-07-10 | Everest Medicines (China) Co., Ltd. | Cancer vaccines and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| WO1993025673A1 (en) | 1992-06-04 | 1993-12-23 | The Regents Of The University Of California | In vivo gene therapy with intron-free sequence of interest |
| US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
| EP0681483B1 (en) | 1993-01-26 | 2005-08-24 | The Trustees of the University of Pennsylvania (a corporation of Pennsylvania) | Compositions and methods for delivery of genetic material |
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| NL9401820A (nl) | 1994-11-02 | 1996-06-03 | Meyn Maschf | Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte. |
| US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| CA2285056C (en) | 1997-04-03 | 2004-12-14 | Iacob Mathiesen | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| CN1261807A (zh) | 1997-06-30 | 2000-08-02 | 罗纳-布朗克罗莱尔股份有限公司 | 向横纹肌中转移核酸的改进方法和用于实施该方法的组合 |
| EP2428249B1 (en) | 1998-07-13 | 2015-10-07 | Inovio Pharmaceuticals, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| EP1573004A4 (en) | 2002-11-04 | 2006-08-09 | Advisys Inc | SYNTHETIC MUSCLE PROMOTERS WITH INHERENT CELLS NATURALLY OBTAINING REGULATORY SEQUENCES EXCELLENT ACTIVITIES |
| EP1628749B1 (en) | 2003-05-30 | 2019-07-31 | VGXI, Inc. | Devices and methods for biomaterial production |
| DK2049559T3 (da) * | 2006-07-28 | 2013-03-25 | Univ Pennsylvania | Forbedrede HPV vacciner |
| EP2076531B1 (en) * | 2006-10-12 | 2011-11-23 | Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. | Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof |
| PT2066399T (pt) | 2006-10-17 | 2019-01-11 | Inovio Pharmaceuticals Inc | Dispositivos de eletroporação e métodos de usar os mesmos para eletroporação de células em mamíferos |
| JP5793726B2 (ja) | 2007-05-23 | 2015-10-14 | ブイジーエックスアイ，インコーポレイティド | 高濃度の生物学的に活性な分子を含む組成物とその製造方法 |
| US20140236070A1 (en) * | 2011-07-29 | 2014-08-21 | Kate Broderick | Linear expression cassettes and uses thereof |
| EA034110B1 (ru) * | 2013-03-15 | 2019-12-27 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Противораковые вакцины и способы лечения с их применением |
| WO2014154905A1 (en) | 2013-03-28 | 2014-10-02 | Invectys | A cancer vaccine for dogs |
| US10398769B2 (en) * | 2013-08-06 | 2019-09-03 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
| KR20250002803A (ko) * | 2016-02-05 | 2025-01-07 | 이노비오 파마수티컬즈, 인크. | 암 백신 및 이를 이용하는 치료 방법 |
| US20200147195A1 (en) * | 2017-05-26 | 2020-05-14 | The Wistar Institute Of Anatomy And Biology | Dtert vaccines and methods of treatment using the same |
-
2017
- 2017-02-03 KR KR1020247040786A patent/KR20250002803A/ko active Pending
- 2017-02-03 BR BR112018015893A patent/BR112018015893A2/pt active Search and Examination
- 2017-02-03 JP JP2018540794A patent/JP7123800B2/ja active Active
- 2017-02-03 CN CN201780020641.5A patent/CN108883312B/zh active Active
- 2017-02-03 US US16/075,527 patent/US11007255B2/en active Active
- 2017-02-03 MX MX2018009506A patent/MX2018009506A/es unknown
- 2017-02-03 AU AU2017214656A patent/AU2017214656B2/en active Active
- 2017-02-03 EP EP17748295.7A patent/EP3411122A4/en active Pending
- 2017-02-03 KR KR1020187025572A patent/KR102742526B1/ko active Active
- 2017-02-03 CN CN202410352664.8A patent/CN118184761A/zh active Pending
- 2017-02-03 WO PCT/US2017/016557 patent/WO2017136758A1/en not_active Ceased
- 2017-02-03 CA CA3013718A patent/CA3013718C/en active Active
-
2018
- 2018-08-03 MX MX2023001540A patent/MX2023001540A/es unknown
-
2021
- 2021-04-09 US US17/226,633 patent/US11801288B2/en active Active
-
2023
- 2023-09-22 US US18/472,640 patent/US20240082374A1/en not_active Abandoned
-
2025
- 2025-06-25 US US19/248,819 patent/US20250319178A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019508403A5 (enExample) | ||
| US20230293608A1 (en) | Oncolytic Vaccinia Virus | |
| JP2017513502A5 (enExample) | ||
| JP2019193662A5 (enExample) | ||
| RU2016145464A (ru) | Рекомбинантные вакцинные штаммы listeria и способы их получения | |
| Cerullo et al. | Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans | |
| WO2017205810A8 (en) | Neoepitope vaccine compositions and methods of use thereof | |
| PH12020500670A1 (en) | Molecular adjuvant | |
| JP2016516723A5 (enExample) | ||
| JP2016539946A5 (enExample) | ||
| JP2016505635A5 (enExample) | ||
| WO2017209053A1 (ja) | 新規な遺伝子組換えワクシニアウイルス | |
| JP2016533749A5 (enExample) | ||
| WO2018228538A1 (zh) | 重组单纯疱疹病毒及其制备方法和应用 | |
| RU2019107976A (ru) | Композиция вакцины | |
| MA40228A (fr) | Souche de listeria recombinée exprimant des protéines de fusion à antigène hétérologues et procédés pour les utiliser | |
| JP2016531927A5 (enExample) | ||
| RU2015103758A (ru) | Днк-вакцина для применения у пациентов с раком поджелудочной железы | |
| JP2014207903A5 (enExample) | ||
| JP2015506179A5 (enExample) | ||
| JP2019531293A5 (enExample) | ||
| JP2020511139A5 (enExample) | ||
| WO2011119925A3 (en) | Synthetic herpes simplex viruses for treatment of cancers | |
| MX2019000215A (es) | Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso. | |
| RU2019132253A (ru) | Новая днк-вакцина, нацеленная на pd-l1, для иммунотерапии рака |